HEMOPOIESIS-ENHANCING ERYTHRO- AND LEUKOPOIESIS STIMULATOR, IMMUNOMODULATOR AND ANTIBACTERIAL AGENT

Description
A new medicinal product with a wide spectrum of action, COBAZOLE®, has been designed for hemopoiesis stimulation. Its operation mechanism is similar to that of natural hemopoiesis stimulators. The product has no analogs in structure and action both in Russia and abroad. COBAZOLE® is designed for the treatment of post hemorrhagic, hyper chromic and hypotactic anemia including those resistant to ferrous preparations. It is also used for the treatment of leucopenia caused by ionizing radiation. COBAZOLE® increases both the numbers of leukocytes and platelets. In addition, it corrects parameters of leukocyte formula. The immunomodulation effect of COBAZOLE® is proved by increased number of lymphocytes and enhanced phagocyte activity of neutrophils. Its pronounced antibacterial properties surpass those of streptomycin by 2-3 times with respect to Staphylococcus; it is more active than tetracycline with respect to Proteus, Klebsiella rhinoscleromatis, Bluepus bacillus, and Staphylococcus. Thus, application of COBAZOLE® in anemia and leucopenia treatment is considerably extended.

Technical appraisal and economic benefits
COBAZOLE® exhibits stronger effect as compared to the well-known hemopoiesis stimulators (Vitamin B_{12}, ferrous preparations, and leucogen). The action of COBAZOLE® on leucopenia is 5-6 times stronger than that of leucogen. The one-stage method for COBAZOLE® synthesis is economically sound and feasible.

Application areas
The application of COBAZOLE® in medicine (antitumor radiation- and chemotherapy) allows recovering normal amounts of leukocytes.

Development stage
Medicinal and biological trials have been completed. Temporary Pharmacopoeia Articles for the drug-substance and pharmaceutical form of COBAZOLE® have been developed. COBAZOLE® is approved and registered in the Pharmacopoeia Committee of the Ministry of Health of the Russian Federation. Clinical trials (I and II phases) have been performed to test the method of treatment of various anemia with COBAZOLE®; methodological guidelines for practical application have been elaborated. Technical and economical assessment and laboratory regulations on COBAZOLE® production have been developed by the A.E. Favorsky Irkutsk Institute of Chemistry SB RAS. The technology of producing pharmaceutical composition COBAZOL® has been commercialized at the ‘Irkutsk Immunopreparations’ Plant.

Patent situation
COBAZOLE® is protected by RF patent (2000).

Commercial offers
Investment contract for product commercialization.

Estimated Cost
US$ 7 per 1 package of the product (10 ampoule). COBAZOLE® brand is registered.
Contacts
Cand.Sc. Margarita L. Al’pert, Scientific Secretary
A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences
1, Favorsky St., Irkutsk, 664033, Russia
Phone: (3952) 42-59-00
Fax: (3952) 41-93-46
E-mail: admin@irioch.irk.ru
http://www.inchemistry.irk.ru